The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period. Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Pea F., Viale P., Damiani D., Pavan F., Cristini F., Fanin R., et al. (2005). Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: Helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 49(8), 3550-3553 [10.1128/AAC.49.8.3550-3553.2005].
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: Helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure
Pea F.;Viale P.;Damiani D.;Cristini F.;
2005
Abstract
The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period. Copyright © 2005, American Society for Microbiology. All Rights Reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
